Effects of Prostamide/Prostaglandin F Synthase on Melanogenesis and Tumor Metastatic Potential of B16 Melanoma

Authors

  • Anzu Yamagishi

DOI:

https://doi.org/10.47750/pnr.2022.13.03.012

Keywords:

CRISPR/Cas9, matrix metalloproteinase-2, melanin, PM/PGFS

Abstract

Introduction: Prostaglandin (PG) F2a and prostaglandin ethanolamide (prostamide, PM) F2a are cyclooxygenase-catalyzed metabolites of
arachidonic acid and arachidonyl etanolamide (anandamide), respectively. PM/Prostaglandin F synthase (PM/PGFS) catalyzes the conversion
of PGH2
to PGF2a and PMH2
to PMF2a. In this study, we established PM/PGFS-knock out (KO) B16 melanoma cells to analyze the role of
PM/PGFS in melanogenesis and tumor metastatic potential.
Methods: PM/PGFS-KO B16 melanoma cells were generated by genome editing using CRISPR/Cas9 and cultured as single cells by limited
dilution. We measured PGF2a and melanin contents and assessed cell growth, matrix metalloproteinase-2 (MMP-2, type IV collagenase)
levels, and intracellular signaling molecules such as CREB, AKT, JNK, and p38. Tumor metastasis in the lungs was evaluated by intravenous
injection of B16 melanoma cells into mice.
Results: PM/PGFS deletion decreased PGF2a production; however, it did not alter melanogenesis, cell growth, MMP-2 levels, intracellular
signaling, and tumor metastasis.
Conclusion: PM/PGFS enzyme has no effects on melanogenesis, cell growth, and tumor metastasis in the B16 melanoma cells.

Downloads

Published

2022-09-20

Issue

Section

Articles

How to Cite

Effects of Prostamide/Prostaglandin F Synthase on Melanogenesis and Tumor Metastatic Potential of B16 Melanoma. (2022). Journal of Pharmaceutical Negative Results, 13(3), 79-84. https://doi.org/10.47750/pnr.2022.13.03.012